Navigation Links
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
Date:6/8/2009

ical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer.

In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma. Micromet also has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to licen
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
2. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
3. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
4. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
5. Micromet Key Events for 2009
6. Micromet Expands Committed Equity Financing Facility to $75 Million
7. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
8. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
9. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Kan. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Trust Alliance (HITRUST) under its Common Security Framework ... Enterprise Security and Privacy Manager, "We appreciate this ... level of commitment that this certification signifies. Our ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s ...
(Date:8/21/2014)... YORK , August 21, 2014 ... Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license ... software for plant breeders and researchers, today is ... a joint venture with Seach Ltd, a leading ... formed to research and develop new breeds of ...
(Date:8/21/2014)... Aug. 21, 2014 InfinityQS International, Inc., ... Manufacturing Intelligence , today announces Infusion Chicago, its ... will be held Oct. 9-10, 2014, at the ... to showcase the necessity for implementing a quality ... Manufacturing Intelligence to gain insight into production processes. ...
Breaking Medicine Technology:ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
... Therapeutics, Inc., a privately held biopharmaceutical company, today ... trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational ... famotidine. The analysis, which was designed to ... anti-inflammatory drug (NSAID)-associated ulcers, was presented at the ...
... LAKES, N.J., Oct. 26 Executives for Medco Health ... present at the following investor conferences: , Timothy Wentworth, ... Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, ... in New York; , David B. Snow Jr., Medco ...
Cached Medicine Technology:Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 2Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 3Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 4Medco to Present at November 2009 Investor Conferences 2
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
(Date:8/22/2014)... first time an oncogenic somatic mutation at amino acid ... been identified in small cell lung cancer (SCLC) tumors ... lines produced increased intracellular signaling and cell growth. , ... representing 15% of all lung cancers and is strongly ... cancer, has been extensively examined for genomic alterations and ...
(Date:8/22/2014)... Rheumatoid arthritis (RA), a complex autoimmune disease ... requires patients to not only cope with pain, ... such as disrupted work, family life and marital ... patients, residual pain and disability is common. In ... their high cost or side effects. Because of ...
(Date:8/22/2014)... 22, 2014 Restore My Vision ... Dr. Samantha Pearson to help people discover how they ... vision surgery by instead improving their eyesight naturally has ... review. , “There’s a reason why the glasses ... each year—it’s because people just assume that it’s their ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4
... Live ForeverNEW YORK, April 28 The hottest new self-help ... TRANSCEND: Nine Steps to Living Well Forever ... and anti-aging authority Dr. Terry Grossman ... the breakthrough scientific findings on life extension revealed in the ...
... Disease Expert Available to Comment on Swine Flu ... AmeriCares, a nonprofit humanitarian aid organization, ... help several Texas health clinics treat and prevent ... medicines and other vital supplies. Some clinics report ...
... nation,s leading drugstore will double , ... April 28 CVS/pharmacy, America,s largest retail pharmacy, today ... offers double Extra Bucks rewards to customers purchasing prescriptions ... CVS/pharmacy,s more than 6,900 locations. By simply presenting a ...
... April 28 Ambry Genetics announced today ... certification for Genome Analyzer (GA) Sequencing, gaining ... genomics service providers globally. Illumina Inc., a ... tools to genomics centers worldwide.(Logo: ...
... www.MassageTableDiscounts.com , THE ,SAM,S CLUB OF MASSAGE TABLES, ... Combining the growing popularity of shopping online ... finest massage tables, chairs, supplies, and accessories is ... today,s quality- and spending-sensitive marketplace.Under a special arrangement ...
... by the Institute for Women,s Policy Research:As of this release, ... confirmed in the United States with confirmed cases in six ... its pandemic alert level to Phase 4 for the first ... public health emergency, allowing the distribution of antiviral drugs from ...
Cached Medicine News:Health News:Life Extension Book, TRANSCEND, Hits Bookstores Today 2Health News:CVS/pharmacy Offers Additional Prescription Savings to Help Customers Manage Health Care Costs 2Health News:CVS/pharmacy Offers Additional Prescription Savings to Help Customers Manage Health Care Costs 3Health News:Ambry Genetics Announces Illumina CSPro Certification for GA Sequencing 2Health News:'All Hands On' Sweepstakes Thanks, Draws Industry to Web Site 2Health News:Challenge in Curbing the Spread of Swine Flu: Half of Workforce Lacks Paid Sick Days 2Health News:Challenge in Curbing the Spread of Swine Flu: Half of Workforce Lacks Paid Sick Days 3
... Powerful and Flexible Impact And Impact2 ... different volume ranges, our single channel Impact ... demands of any application. Engineered with the ... our multichannel line, these pipettors are equally ...
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... is a major step forward in ... handling system - with one universal ... modules. All five single channel and ... one handle. The lightweight handle is ...
... solution and best value in high performance ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
Medicine Products: